Table 2.
Marker | Stages III and IV | Stage III | Stage IV | ||||||
---|---|---|---|---|---|---|---|---|---|
AUC | Sensitivity at 90% specificity | Specificity at 90% sensitivity | AUC | Sensitivity at 90% specificity | Specificity at 90% sensitivity | AUC | Sensitivity at 90% specificity | Specificity at 90% sensitivity | |
PZ | 0.60 | 0.22 | 0.06 | 0.68 | 0 | 0.50 | 0.46 | 0 | 0.10 |
SHBG | 0.60 | 0.27 | 0 | 0.57 | 0.27 | 0 | 0.69 | 0.33 | 0.28 |
VWF | 0.59 | 0.08 | 0.04 | 0.72 | 0.09 | 0.38 | 0.49 | 0.20 | 0.17 |
CA19-9 | 0.65 | 0.23 | 0.38 | 0.58 | 0.18 | 0.50 | 0.65 | 0.20 | 0.44 |
PZ + CA19-9 | 0.66 | 0.22 | 0.33 | 0.73 | 0 | 0.625 | 0.70 | 0 | 0.40 |
SHBG + CA19-9 | 0.62 | 0.12 | 0.38 | 0.72 | 0.45 | 0.25 | 0.78 | 0.33 | 0.22 |
VWF + CA19-9 | 0.67 | 0.19 | 0.38 | 0.73 | 0.09 | 0.5 | 0.69 | 0.20 | 0.50 |
PZ + SHBG | 0.60 | 0.17 | 0.22 | 0.70 | 0.18 | 0.5 | 0.79 | 0.43 | 0.30 |
PZ + VWF | 0.64 | 0.11 | 0.22 | 0.72 | 0 | 0.50 | 0.46 | 0 | 0.10 |
SHBG + VWF | 0.58 | 0.08 | 0.04 | 0.80 | 0.36 | 0.38 | 0.72 | 0.47 | 0.33 |
PZ + SHBG + CA19-9 | 0.64 | 0.17 | 0.33 | 0.78 | 0.27 | 0.50 | 0.87 | 0.86 | 0.40 |
PZ + VWF + CA19-9 | 0.73 | 0.11 | 0.39 | 0.77 | 0 | 0.75 | 0.70 | 0.29 | 0.40 |
SHBG + VWF + CA19-9 | 0.68 | 0.23 | 0.38 | 0.83 | 0.36 | 0.50 | 0.77 | 0.47 | 0.22 |
PZ + SHBG + VWF | 0.65 | 0.17 | 0.33 | 0.75 | 0.18 | 0.50 | 0.80 | 0.86 | 0.40 |
PZ + SHBG + VWF + CA19-9 | 0.71 | 0.11 | 0.39 | 0.83 | 0.27 | 0.63 | 0.87 | 0.71 | 0.30 |
These proteins were tested as single or composite biomarker for predicting Good-responders from Limited-responders with or without inclusion of CA 19-9. PZ is a vitamin K-dependent glycoprotein, which regulates blood coagulation. SHBG is a glycoprotein that binds hormones, which is an index of testosterone level and an inflammatory marker. VWF is a blood glycoprotein maintaining hemostasis, which also acts in inflammation and antitumor